ofloxacin has been researched along with Infectious Diseases in 2 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The population pharmacokinetics of levofloxacin (LVFX), the l-enantiomer of ofloxacin, were studied in 522 subjects, including normal subjects and patients with infectious diseases." | 7.69 | Premarketing population pharmacokinetic study of levofloxacin in normal subjects and patients with infectious diseases. ( Hori, R; Kagimoto, N; Nomura, H; Okumura, K; Tanigawara, Y, 1995) |
| "The population pharmacokinetics of levofloxacin (LVFX), the l-enantiomer of ofloxacin, were studied in 522 subjects, including normal subjects and patients with infectious diseases." | 3.69 | Premarketing population pharmacokinetic study of levofloxacin in normal subjects and patients with infectious diseases. ( Hori, R; Kagimoto, N; Nomura, H; Okumura, K; Tanigawara, Y, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Viale, P | 1 |
| Scudeller, L | 1 |
| Cristini, F | 1 |
| Tanigawara, Y | 1 |
| Nomura, H | 1 |
| Kagimoto, N | 1 |
| Okumura, K | 1 |
| Hori, R | 1 |
2 other studies available for ofloxacin and Infectious Diseases
| Article | Year |
|---|---|
Levofloxacin: a suitable option for the infectious disease consultant.
Topics: Anti-Bacterial Agents; Communicable Diseases; Critical Illness; Cross Infection; Humans; Intensive C | 2004 |
Premarketing population pharmacokinetic study of levofloxacin in normal subjects and patients with infectious diseases.
Topics: Age Factors; Bayes Theorem; Clinical Trials as Topic; Communicable Diseases; Humans; Levofloxacin; M | 1995 |